Boltz PBC, an applied artificial intelligence research company focused on biomolecular modeling, has announced a new collaboration with Takeda aimed at bringing advanced AI-driven tools to scientists across the pharmaceutical company’s global research organization.
The partnership is designed to help accelerate drug discovery by providing Takeda researchers with direct access to Boltz’s latest proprietary biomolecular foundation models. These include BoltzMol-1 and BoltzProt-1, two recently unveiled AI models developed to support molecular structure prediction, protein design, affinity estimation, and generative drug design.
The collaboration marks another step in the growing adoption of artificial intelligence across the pharmaceutical industry, where companies are increasingly turning to advanced computational tools to improve research efficiency and identify promising drug candidates more quickly.
Under the agreement, Takeda scientists will gain access to the full Boltz platform, including the Boltz Lab interface and the Boltz API. The platform is intended to integrate seamlessly into existing research workflows, allowing scientists from different disciplines to use AI-powered capabilities without requiring extensive machine learning expertise.
One notable aspect of the platform is its ability to work alongside large language model-based agents. Through natural language prompts, researchers can coordinate complex molecular design and prediction tasks, potentially reducing the time required to evaluate and optimize new therapeutic candidates.
The collaboration also includes a scientific partnership between the two organizations. Boltz researchers will work directly with Takeda teams on selected discovery programs, helping fine-tune AI models for specific biological targets and research objectives. Any compounds generated through the use of the platform will remain the property of Takeda, ensuring the company retains ownership of intellectual property arising from its research efforts.
Gabriele Corso, Co-founder and Chief Executive Officer of Boltz, said the agreement reflects the company’s mission to make advanced AI tools practical and accessible for drug discovery teams.
He noted that researchers across a range of disciplines—including medicinal chemistry, protein engineering, computational biology, and machine learning—will be able to access the company’s most sophisticated models through user-friendly interfaces, application programming interfaces, and AI agent integrations. Corso added that Boltz is eager to see how Takeda scientists apply these technologies to advance their research programs.
Takeda also emphasized the strategic importance of artificial intelligence in its research operations. Hans Bitter, Head of Computational Science and Data Strategy at Takeda Research, said the company is actively combining cutting-edge science with the latest AI innovations to improve the speed and quality of drug discovery.
According to Bitter, deploying Boltz’s frontier biomolecular models across Takeda’s research organization will provide scientists with practical tools to support structure prediction, molecular design, and the advancement of high-quality discovery programs.
As pharmaceutical companies continue to invest heavily in AI-driven research, collaborations such as this highlight how advanced computational models are moving from experimental technologies to everyday tools that support scientific decision-making. By combining Takeda’s drug discovery expertise with Boltz’s rapidly evolving AI platform, the two organizations hope to accelerate the identification and development of future therapies for patients worldwide.